ABSTRACT

Background: Diabetes mellitus has become one of the biggest health problems of this era. The resultant microvascular and macrovascular complications add to significant amount of morbidity and mortality. Urine microalbumin is considered as an early marker for microvascular complications among diabetic patients. The aim of this study was to find out the prevalence of microalbuminuria among type 2 diabetic patients attending Kathmandu Medical College and its relation with glycemic control, age, sex, duration of diabetes.

Methods: A total of 208 previously diagnosed type 2 diabetic patients attending medical outpatient department of Kathmandu Medical College, Sinamangal were included in the study over a period of 1 year (October 2017 - September 2018). Fasting and 2-hour postprandial venous blood for blood glucose and HbA1c measurement and early morning urine sample (after overnight fast) was collected for detection of microalbuminuria. Statistical analysis was done using SPSS version 23.

Results: The prevalence of microalbuminuria among the study population (mean age: 54.22 ± 11.76 years, mean HbA1c: 7.62 ± 1.53 %) was 42.8%. Microalbuminuria had significant correlation with HbA1c and duration of diabetes (p<0.001), but not with age, sex and type of medication. There was positive correlation between urine microalbumin and fasting and post-prandial blood glucose.

Conclusions: Our present study found high prevalence of microalbuminuria among diabetic patients with poor glycemic control. It is suggested that tighter glycemic control with regular urine microalbumin testing should be integral part of diabetic management plan to prevent long term complications such as diabetic nephropathy.
to the burden of disease. Diabetic nephropathy, as defined as diabetes with albuminuria or impaired glomerular filtration rate, or both is one of the frequent microvascular complications with variable prevalence (2.2% - 14.2 %) in different population. Microalbuminuria is considered as an early marker of diabetic nephropathy, with higher levels of urinary albumin representing a generalized vascular damage rather than renal microvascular injury alone. In recent years, the incidence of end stage renal disease (ESRD) has increased drastically that has been attributed to increased incidence of diabetes mellitus in the general population. Diabetic nephropathy has been reported as one of the leading etiologies of ESRD in Nepal.

Glycosylated hemoglobin (HbA1c) is used as a marker of blood glucose control in the diabetic patients. It determines average glycemic control over a period of 8-12 weeks and its higher values correlate with the development of microvascular complications in the diabetic patients. The Diabetes Control and Complications Trial (DCCT) and United Kingdom Prospective Diabetic Study (UKPDS) highlighted the fact that careful monitoring and control of glycemia (HbA1c≤ 7.0 %) in patients with T2DM decreased the possibility of developing microalbuminuria by 34% and therefore, maintaining optimal HbA1c has been advised for all diabetic patients to prevent such complications.

With the rise in the patients with T2DM in Nepal and the well-known importance of early diagnosis, treatment and prevention of microalbuminuria in this population, this study was aimed at describing the prevalence of microalbuminuria in T2DM patients, the patient characteristics and evaluating the relationship between microalbuminuria and glycemic control.

METHODS

A cross-sectional study was conducted from October 2017 to September 2018. Ethical clearance was obtained from the Institutional Review Committee (IRC) of Kathmandu Medical College(Ref No. 02082017). The study group comprised of 208 previously diagnosed type 2 diabetic patients (duration of diabetes > 6 months) attending medical outpatient department of Kathmandu Medical College, Sinamangal. Exclusion criteria were patients with newly diagnosed diabetes mellitus, patients with other causes of proteinuria, hematuria and renal failure, recent history of urinary tract infection and presence of any self-reported acute illness or fever after taking detailed history and observing previous medical records.

After taking written consent from the research participants during their outpatient visits, an interviewer-administered questionnaire was completed that included socio-demographic data and detailed medical history including the list of current medication. Two blood samples (5 ml) were drawn in the morning after overnight fasting (minimum 8 hours) for estimation of serum fasting blood glucose (FBG) and whole-blood HbA1c whereas the second blood sample was drawn 2 h after an average meal by the patients for estimation of serum post-prandial blood glucose (PPBG). A single spot urine sample was collected in the early morning after overnight fasting. Blood glucose was determined by Selectra Pro M analyzer (EliTech Clinical Systems) using enzymatic colorimetric method (GOD/POD/PAP method).

HbA1c (Glycated hemoglobin) was measured using chromatographic technique by D-10TM Hemoglobin analyzer (Bio-Rad Laboratories, Inc.). Based on HbA1c values, the glycemic control was categorized into: a) good control (≤ 7.0 %), b) fair control (7.01 - 8.20 %), and c) poor control (> 8.20 %). Urinary albumin was measured by point-of-care NycocardTM urinary-albumin test. In controlled laboratory testing, a precision of <10% expressed by the coefficient of variation (CV) is usually achieved for the test. A diagnosis of microalbuminuria was made if urinary albumin was ≥ 20 mg/L up to 200 mg/L. Values above 200 mg/L were classified as clinical albuminuria.

Data was collected, compiled and analyzed by using Statistical Package of Social Science (SPSS) software version 23. The data were expressed as mean ± SD or median (minimum-maximum) as appropriate. The mean and median comparisons of different variables between no-microalbuminuria and microalbuminuria-present groups was done by student’s t-test and Mann-Whitney U-test respectively. The difference in proportions was
analyzed by chi-square test. The association between HbA1c and microalbuminuria was determined by Spearman’s rank correlation coefficient. P-value of < 0.05 was considered to be statistically significant.

RESULTS

A total of 208 diabetic patients (mean age: 54.22 ± 11.76 years, age ranging from 29 – 84 years) were included in the study. There were 97 males (46.6 %) and 111 females (53.4 %). The median duration of diabetes was 5 years (Range: 0.5 – 21 years). 81.3 % of the patients were using oral hypoglycemic agents (OHAs), and the remaining 18.8 % were using insulin. The mean HbA1c of the study population was 7.62 ± 1.53 %. Sub-dividing the study group based on glycemic control, approximately only one-third of the patients (36.5 %) had good glycemic control [Table 1].

Table 1: Frequency and mean HbA1c (%) of the patients based on glycemic control status

| Glycemic control group | No. of patients | Percentage (%) | HbA1c (mean ± SD) % |
|------------------------|-----------------|----------------|---------------------|
| Good control           | 76              | 36.5 %         | 6.18 ± 0.51 %       |
| Fair control           | 82              | 39.4 %         | 7.59 ± 0.35 %       |
| Poor control           | 50              | 24.0 %         | 9.85 ± 1.04 %       |
| Total                  | 208             | 100.0 %        |                     |

In the study population, 89/208 patients (42.8 %) had microalbuminuria and 55.8 % didn’t have the condition. 3 of the patients had clinical albuminuria i.e. above the range for definition of microalbuminuria and these were excluded from further analysis[Table 2].

Table 2: Frequency of patients based on microalbuminuria status

| Status                  | No. of patients | Percentage (%) |
|-------------------------|-----------------|----------------|
| No microalbuminuria     | 116             | 55.8 %         |
| Microalbuminuria        | 89              | 42.8 %         |
| Clinical albuminuria    | 3               | 1.4 %          |

The diabetic patients who had microalbuminuria had significantly longer duration of disease and higher mean HbA1c levels compared to the patients without microalbuminuria. The two groups were not different in age, sex and medication use distribution [Table 3].

Table 3: Demographic variables and HbA1c of the patients expressed as mean ± SD or frequency or median (minimum- maximum) as appropriate based on microalbuminuria status

| Variables                   | Microalbuminuria status | Chi-Square |
|-----------------------------|-------------------------|------------|
|                            | No microalbuminuria (n= 116) | Microalbuminuria present (n = 89) |         |
| Age (years)                 | 53.07 ± 12.06            | 56.16 ± 11.07 | 0.06     |
| Sex (Male/Female)           | 52/64                    | 43/46       | 0.62     |
| Medication use (OHA/Insulin)| 99/17                    | 67/22       | 0.07     |
| Duration of diabetes (years)| 4.00 (0.50 – 20.00)     | 8.00 (0.50 – 21.00) | < 0.001 |
| HbA1c (%)                   | 6.93 ± 0.94              | 8.45 ± 1.65 | < 0.001 |
Glycemic control (expressed as HbA1c) was positively correlated with microalbuminuria status (Spearman’s rho = 0.478, P< 0.001). On post-hoc contingency table analysis (using adjusted residual method), the proportion of patients with microalbuminuria was significantly higher in poor glycemic control group compared to good glycemic control group (46.1 % vs. 18.1 %, P <0.001). Conversely, the good glycemic control group had a far greater proportion of patients without microalbuminuria compared to poor glycemic control group (50.9 % vs. 6.0 %, P< 0.001).

In the present study, 208 patients were studied and the overall prevalence of microalbuminuria was found to be 42.8%. A study conducted by Sigdel et al14 in Pokhara(45.5%) and and Khadka B et al15 in Rupandehi (46.5%) reported similar prevalence. Similarly, Ambayiram et al.16 also reported comparable prevalence of microalbuminuria with 41.5% in Chidambaram, India. The prevalence, however, have differed significantly in different studies (such as a lower prevalence of 14.2% in a study by Ardekani et al6). This variation may be due to different factors like differences in the study population, techniques used for urine collection, time and amount of urine collected, differences in methods of measuring microalbuminuria, criteria for defining microalbuminuria etc. The mean HbA1c of the study population was 7.62 ± 1.53 %.24% had poor glycemic control. The prevalence of microalbuminuria was significantly higher in poor glycemic control group compared to good glycemic control group, strongly supporting findings from previous studies.17,18 Several studies have revealed age, sex, duration of diabetes, body mass index and poor glycemic control as risk factors for development of microalbuminuria.7,16,18 Our study showed that patients with microalbuminuria had longer duration of disease and higher HbA1c levels. The presence of microalbuminuria was not affected by age, sex and type of medication used.6,14 Therefore, it can be concluded from our study that good glycemic control and early diagnosis of diabetes and institution of therapy are the two important predictors of development of microalbuminuria in these patients.

In our study, we found significant correlation between HbA1c and microalbuminuria as supported by earlier studies.7,17,18 However, there are studies that did not show significant association between these two.19 These differences in findings may be due to limited sample size, less time allocation for the duration of study or variation in stage of the disease in study population. The urine microalbumin had significant positive correlations with both fasting and post-prandial blood glucose, supporting the outcome of previously conducted studies.7,18 This highlights the fact that diabetic patients should have tighter control of blood glucose to minimize microvascular complications.

One important aspect to consider is the hospital-based nature of our study that has introduced selection bias and therefore, might not be true
representative of the diabetic population. There is scope of further study including important variables among larger diabetic population.

CONCLUSION

There is a high prevalence of microalbuminuria in patients with type 2 diabetes mellitus, which is associated with longer duration of disease and poor glycemic control. Regular testing of HbA1c and urine microalbumin should be an integral part of diabetic patient management (particularly for the patients with long duration of disease) to prevent and early-diagnose renal complications associated with the condition.

REFERENCES

1. Defronzo RA. Pathogenesis of type 2 diabetes mellitus: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev. 1997;5:177-269.

2. ADA. Diagnosis and classification of diabetes mellitus. Diabetes care 2014 Jan;Suppl 1:S81-90. doi: 10.2337/dc14-S081.

3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes care. 2004;27(5):1047-53. PMID: 15111519.

4. Gyawali B, Sharma R, Neupane D, Mishra SR, van Teijlingen E, Kallestrup P. Prevalence of type 2 diabetes in Nepal: a systematic review and meta-analysis from 2000 to 2014. Global Health Action. 2015;8:29088. doi:10.3402/gha.v8.29088.

5. de Boer IH, RueTC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305(24): 2532-9. doi: 10.1001/jama.2011.861.

6. Afkhami-Ardekani M, Modarresi M, Amirchaghmaghi E, Prevalence of microalbuminuria and its risk factors in type 2 diabetic patients. Indian J Nephrol.,2008; 18(3):112-7. doi: 10.4103/0971-4065.43690.

7. Varghese A, Deepa R, Rema M, Mohan V. Prevalence of microalbuminuria in type 2 diabetes mellitus at a diabetes centre in southern India. Postgrad Med J. 2001;77:399-402. doi:10.1136/pmj.77.908.399

8. Raij L. Recommendations for the management of special populations: Renal disease in diabetes. Am J Hypertens. 2003;16:465–95. doi:10.1016/j.amjhyper.2003.07.006

9. Bartaula B, Subedi M, Kumar M et al. Spectrum of complications in chronic kidney disease patients undergoing maintenance hemodialysis: An experience of a tertiary care center in Nepal. Saudi J Kidney Dis Transpl. 2019; 30(1): p. 208-214. PMID: 30804283.

10. Jesudason DR, Dunstan K, Leong D, Wittert GA. Macrovascular Risk and Diagnostic Criteria for Type 2 Diabetes. Diabetes Care 2003; 26: 485-90. PMID: 12547886.

11. Fioretto P, Bruseghin M, Berto I, Gallina P, Manzato E, Mussap M. Renal protection in diabetes, role of glycemic control. J Am Soc Nephrol 2006; 17: 86-9. doi:10.1681/ASN.2005121343.

12. Diabetes control and complication trial research group. The relationship of glycemic exposure (Hba1C) to the risk of development and progression of retinopathy in the diabetes control and complication trial. Diabetes. 1995;44:968–83. PMID:7622004.

13. Hirsch I.B. Glycemic Variability and Diabetes Complications: Does It Matter? Of Course It Does!. Diabetes Care, 2015. 38(8): p. 1610-4. doi: 10.2337/dc14-2898.

14. Sigdel M, Rajbhandari N, Basnet S, Nagila A, Basnet P, Tamrakar BK. Microalbuminuria among type 2 diabetes mellitus patients in Pokhara, Nepal. Nepal Med Coll J 2008;10(4):242-5. PMID: 19558062.

15. Khadka B, Tiwari ML, Timalsina B, Risal P, Gupta S, Acharya D. Prevalence and factors associated
with microalbuminuria among type 2 diabetic patients: A hospital based study. J Nepal Med Assoc. 2018 Jan-Feb;56(209):516-21. PMID: 30058635.

16. Ambayiram AV, Kalyani P, Felix AJW, Govindarajan PK. Prevalence of microalbuminuria among type II diabetic mellitus patients in urban Chidambaram. Saudi J Med. 2016;1(3):57-62. doi: 10.21276/sjm.2016.1.3.1

17. Goyal B, Goyal J, Sinha M, Fiza B, Sharma P, Bhandari S et al. Association of glycosylated hemoglobin with microalbuminuria in patients with type 2 diabetes mellitus. International Journal of biotechnology and biochemistry 2017;13(4):311-23.

18. Sheikh SA, Baig JA, Iqbal T, Kazmi T, Baig M, Husain SS. Prevalence of microalbuminuria with relation to glycemic control in type 2 diabetic patients in Karachi. J Ayub Med Coll 2009;21(3);83-6. PMID: 20929021.

19. Maharjan BR, Bhandary S, Risal P, Sedhain A, Shakya PR, Gautam M. Microalbuminuria and macroalbuminuria in type 2 diabetes. J Nepal Health Res Counc 2010 Oct;8(17):110-15. PMID: 21876575.